Overview

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

Status:
NOT_YET_RECRUITING

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Phase:

PHASE2

Details

Lead Sponsor:

Halia Therapeutics, Inc.

Treatments:

semaglutide